PARP inhibitors: A new era of targeted therapy

Maturitas

Volumn 81, Issue 1, 2015, Pages 5-9

  Tangutoori, Shifalika ^a,b   Baldwin, Paige ^a   Sridhar, Srinivas ^a,c  

^a NORTHEASTERN UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

BMN 673; Lynparza; Olaparib; PARP inhibitors; Personalized medicine

Indexed keywords

ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG RESISTANCE; HUMAN; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; SIGNAL TRANSDUCTION; FEMALE; GENETICS; MALE; MUTATION; NEOPLASMS; PERSONALIZED MEDICINE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PRECISION MEDICINE;

EID: 84928060317     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2015.01.015     Document Type: Review

References (29)

1. G. de Murcia, J. Menissier-de Murcia, and V. Schreiber Poly(ADP-ribose) polymerase: molecular biological aspects BioEssays 13 9 1991 455 462 (news and reviews in molecular, cellular and developmental biology)
2. D. D'Amours, S. Desnoyers, I. D'Silva, and G.G. Poirier Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions Biochem J 342 Pt 2 1999 249 268
3. J.F. Liu, P.A. Konstantinopoulos, and U.A. Matulonis PARP inhibitors in ovarian cancer: current status and future promise Gynecol Oncol 133 2 2014 362 369
4. J. Murai, S.Y. Huang, and A. Renaud Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol Cancer Ther 13 2 2014 433 443
5. D. Bertwistle, and A. Ashworth The pathology of familial breast cancer: how do the functions of BRCA1 and BRCA2 relate to breast tumour pathology? Breast Cancer Res (BCR) 1 1 1999 41 47
6. M.J. Schiewer, J.F. Goodwin, and S. Han Dual roles of PARP-1 promote cancer growth and progression Cancer Discov 2 12 2012 1134 1149
7. R. Scully Role of BRCA gene dysfunction in breast and ovarian cancer predisposition Breast Cancer Res: BCR 2 5 2000 324 330
8. S. Fan, J.A. Wang, and R.Q. Yuan BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins Oncogene 16 23 1998 3069 3082
9. E.M. Rosen, S. Fan, and I.D. Goldberg BRCA1 and prostate cancer Cancer Invest 19 4 2001 396 412
10. S.K. Sandhu, A. Omlin, and L. Hylands Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer Ann Oncol 24 5 2013 1416 1418 (official journal of the European Society for Medical Oncology/ESMO)
11. A. Sonnenblick, E. de Azambuja, H.A. Azim Jr., and M. Piccart An update on PARP inhibitors - moving to the adjuvant setting Nat Rev Clin Oncol 12 1 2015 27 41 10.1038/nrclinonc.2014.163 Epub 2014 Oct 7
12. J.C. Brenner, B. Ateeq, and Y. Li Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer Cancer Cell 19 5 2011 664 678
13. R. Mehra, S.A. Tomlins, and J. Yu Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer Cancer Res 68 10 2008 3584 3590
14. E. Stewart, R. Goshorn, and C. Bradley Targeting the DNA repair pathway in Ewing sarcoma Cell Rep 9 3 2014 829 840
15. E. Gonzalez-Billalabeitia, N. Seitzer, and S.J. Song Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition Cancer Discov 4 8 2014 896 904
16. N. Johnson, Y-C. Li, and Z.E. Walton Compromised cdk1 activity sensitizes BRCA-proficient cancers to PARP inhibition Nat Med 17 7 2011 875 882
17. C.J. Lord, and A. Ashworth Mechanisms of resistance to therapies targeting BRCA-mutant cancers Nat Med 19 11 2013 1381 1388
18. C. To, E.H. Kim, and D.B. Royce The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice Cancer Prev Res (Philadelphia, PA) 7 7 2014 698 707
19. J.M. Albert, C. Cao, and K.W. Kim Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models Clin Cancer Res 13 10 2007 3033 3042
20. L. Barazzuol, R. Jena, and N. Burnet Evaluation of poly(ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma Radiat Oncol 8 1 2013 65
21. C. Donawho, Y. Luo, and Y. Luo ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models Clin Cancer Res 13 2007 2728 2737
22. F. Dungey, and D.A. Löser Chalmers A: replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential Int J Radiat Oncol Biol Phys 72 2008 1188 1197
23. R. Plummer, P. Lorigan, and N. Steven A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation Cancer Chemother Pharmacol 71 5 2013 1191 1199
24. R. Plummer, P. Stephens, and L. Aissat-Daudigny Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors Cancer Chemother Pharmacol 74 2 2014 257 265
25. J. Samol, M. Ranson, and E. Scott Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study Invest New Drugs 30 4 2012 1493 1500
26. A. Chalmers Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors Anticancer Agents Med Chem 10 2010 520 533
27. E. Efimova, H. Mauceri, and D. Golden Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence inirradiated breast cancer cells and tumors Cancer Res 70 2010 6277 6282
28. P. Bouwman, and J. Jonkers Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 20 3 2014 540 547 (an official journal of the American Association for Cancer Research)
29. S. Tangutoori, H. Korideck, M. Makrigiorgos, R. Cormack, and S. Sridhar Abstract A81. A novel nano-formulation for systemic administration of PARPi-olaparib (Nano-Olaparib) for radiosensitization, chemosensitization, and combinatorial therapy in prostate cancer Mol Cancer Ther 12 11 Suppl. 2013 A81